139 related articles for article (PubMed ID: 16527362)
1. Genetic evidence for the involvement of Fcgamma receptor III in experimental autoimmune myasthenia gravis pathogenesis.
Tüzün E; Saini SS; Yang H; Alagappan D; Higgs S; Christadoss P
J Neuroimmunol; 2006 May; 174(1-2):157-67. PubMed ID: 16527362
[TBL] [Abstract][Full Text] [Related]
2. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis.
Christadoss P; Tüzün E; Li J; Saini SS; Yang H
Ann N Y Acad Sci; 2008; 1132():210-9. PubMed ID: 18567870
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P
Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283
[TBL] [Abstract][Full Text] [Related]
5. Genetic deficiency of estrogen receptor alpha fails to influence experimental autoimmune myasthenia gravis pathogenesis.
Qi H; Li J; Allman W; Saini SS; Tüzün E; Wu X; Estes DM; Christadoss P
J Neuroimmunol; 2011 May; 234(1-2):165-7. PubMed ID: 21481948
[TBL] [Abstract][Full Text] [Related]
6. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
7. ICOS is essential for the development of experimental autoimmune myasthenia gravis.
Scott BG; Yang H; Tüzün E; Dong C; Flavell RA; Christadoss P
J Neuroimmunol; 2004 Aug; 153(1-2):16-25. PubMed ID: 15265659
[TBL] [Abstract][Full Text] [Related]
8. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.
Tüzün E; Scott BG; Goluszko E; Higgs S; Christadoss P
J Immunol; 2003 Oct; 171(7):3847-54. PubMed ID: 14500686
[TBL] [Abstract][Full Text] [Related]
9. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
[TBL] [Abstract][Full Text] [Related]
10. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody.
Tüzün E; Li J; Saini SS; Yang H; Christadoss P
J Neuroimmunol; 2007 Jan; 182(1-2):167-76. PubMed ID: 17137637
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
[TBL] [Abstract][Full Text] [Related]
12. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.
Kaminski HJ; Kusner LL; Richmonds C; Medof ME; Lin F
Exp Neurol; 2006 Dec; 202(2):287-93. PubMed ID: 16859686
[TBL] [Abstract][Full Text] [Related]
13. Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice.
Ulusoy C; Çavuş F; Yılmaz V; Tüzün E
Immunol Invest; 2017 Jul; 46(5):490-499. PubMed ID: 28375749
[TBL] [Abstract][Full Text] [Related]
14. The role of B-cells in experimental myasthenia gravis in mice.
Wang HB; Li H; He B; Bakheit M; Levi M; Wahren B; Berglöf A; Sandstedt K; Link H; Shi FD
Biomed Pharmacother; 1999 Jun; 53(5-6):227-33. PubMed ID: 10424244
[TBL] [Abstract][Full Text] [Related]
15. Targeting classical complement pathway to treat complement mediated autoimmune diseases.
Tüzün E; Li J; Saini SS; Yang H; Christadoss P
Adv Exp Med Biol; 2008; 632():265-72. PubMed ID: 19025128
[TBL] [Abstract][Full Text] [Related]
16. A new mouse model of autoimmune ocular myasthenia gravis.
Yang H; Wu B; Tüzün E; Saini SS; Li J; Allman W; Higgs S; Xiao TL; Christadoss P
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5101-11. PubMed ID: 17962462
[TBL] [Abstract][Full Text] [Related]
17. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis.
Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H
Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409
[TBL] [Abstract][Full Text] [Related]
18. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
19. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
[TBL] [Abstract][Full Text] [Related]
20. Complement associated pathogenic mechanisms in myasthenia gravis.
Tüzün E; Christadoss P
Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]